|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM288805755 |
| 003 |
DE-627 |
| 005 |
20250224041014.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2018.09.009
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0962.xml
|
| 035 |
|
|
|a (DE-627)NLM288805755
|
| 035 |
|
|
|a (NLM)30244152
|
| 035 |
|
|
|a (PII)S1521-6616(18)30299-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Tamminen, Kirsi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Norovirus-specific mucosal antibodies correlate to systemic antibodies and block norovirus virus-like particles binding to histo-blood group antigens
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.10.2019
|
| 500 |
|
|
|a Date Revised 07.10.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2018 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a The best acknowledged correlate of protection from norovirus (NoV) infection is the ability of serum antibodies to block binding of NoV virus-like particles (VLPs) to histo-blood group antigens (HBGAs). We investigated mucosal NoV-specific antibody levels in adult volunteers and used saliva from a single donor to determine whether purified saliva antibodies confer blocking. NoV-specific IgG and IgA levels in saliva and plasma samples were measured against four NoV genotype VLPs. NoV-specific IgG and IgA titers in saliva and plasma samples correlated significantly. Antibodies were detected against all VLPs with the highest level of antibodies directed against ancestral GII.4 99 genotype. Affinity chromatography purified salivary IgA and IgG blocked binding of GII.4 99 VLPs to HBGAs. Saliva sampling is a non-invasive alternative to blood drawing and an excellent biological fluid to study NoV-specific immune responses. Mucosal anti-NoV antibodies block binding of NoV VLPs to HBGAs, and may therefore be protective
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Blocking assay
|
| 650 |
|
4 |
|a Mucosal immunity
|
| 650 |
|
4 |
|a Norovirus
|
| 650 |
|
4 |
|a Saliva
|
| 650 |
|
4 |
|a Secretory IgA
|
| 650 |
|
7 |
|a Antibodies, Blocking
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 650 |
|
7 |
|a Blood Group Antigens
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin A
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin A, Secretory
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 700 |
1 |
|
|a Malm, Maria
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vesikari, Timo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Blazevic, Vesna
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 197(2018) vom: 01. Dez., Seite 110-117
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:197
|g year:2018
|g day:01
|g month:12
|g pages:110-117
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2018.09.009
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 197
|j 2018
|b 01
|c 12
|h 110-117
|